| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals.
|
|
Today’s Big NewsOct 4, 2024 |
| By James Waldron Johnson & Johnson’s deprioritization of its infectious disease pipeline has claimed another victim in the form of its dengue virus vaccine mosnodenvir. |
|
|
|
By Angus Liu BeiGene is pricing Tevimbra at a 10% discount to other PD-1 therapies available in second-line esophageal squamous cell carcinoma. |
By Gabrielle Masson Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the organization. |
By Conor Hale Cologuard Plus represents the next generation of the company's mainstay, at-home screening test for colorectal cancer. |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now!
|
|
By Angus Liu CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. |
By Fraiser Kansteiner While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online. |
By Darren Incorvaia The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals, and even once treated it’s common for the microbe to reinfect patients again and again. |
By Nick Paul Taylor A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care drugs, leading the biotech to enroll a new cohort on a tweaked regimen designed to dial up the efficacy. |
By Andrea Park A nonprofit dedicated to improving vaccination rates to eradicate meningococcal meningitis is brightening things up this World Meningitis Day. |
By Darren Incorvaia,Zoey Becker Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a day after the science underlying Prothena’s Parkinson’s drug prasinezumab was implicated in a massive research misconduct scandal but are unrelated, a company spokesperson told Fierce in an email. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
|
Wednesday, October 16, 2024 | 2pm ET / 11am PT Join experts as they delve into the distinct strategies required for developing ADCs and RIT, focusing on how medical imaging can accelerate clinical trials and drug approval. Register now to gain practical insights into optimizing clinical trials and advancing cancer therapies through cutting-edge imaging techniques.
|
|
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| WhitepaperUnique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
| WhitepaperWhen the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
| WhitepaperPower non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
| WhitepaperFacing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
